(Q43576040)

24 November 2017

1 reference

title

The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors (English)

1 reference

24 November 2017

2

Barney S Graham

1 reference

24 November 2017

1

Richard A Koup

1 reference

24 November 2017

Daniel C Douek

3

1 reference

24 November 2017

17 December 2010

1 reference

Nature Reviews Immunology

24 November 2017

1 reference

24 November 2017

11

1 reference

24 November 2017

1

1 reference

24 November 2017

65-70

1 reference

https://scigraph.springernature.com/pub.10.1038/nri2890

24 November 2017

0 references

cites work

HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response.

1 reference

Trends in HIV-1 incidence in a cohort of prostitutes in Kenya: implications for HIV-1 vaccine efficacy trials

21 January 2018

1 reference

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

21 January 2018

1 reference

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

31 March 2020

1 reference

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand

31 March 2020

1 reference

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

31 March 2020

1 reference

Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know

31 March 2020

1 reference

Vaccines: correlates of vaccine-induced immunity

31 March 2020

1 reference

Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya

31 March 2020

1 reference

Elite control of HIV infection: implications for vaccine design

31 March 2020

1 reference

Tenets of protection from progression to AIDS: lessons from the immune responses to HIV-2 infection.

31 March 2020

1 reference

The immune response during acute HIV-1 infection: clues for vaccine development

31 March 2020

1 reference

A TRIM5alpha exon 2 polymorphism is associated with protection from HIV-1 infection in the Pumwani sex worker cohort

31 March 2020

1 reference

Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi

31 March 2020

1 reference

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

31 March 2020

1 reference

Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma

31 March 2020

1 reference

Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNA

31 March 2020

1 reference

Association of HIV-specific and total CD8+ T memory phenotypes in subtype C HIV-1 infection with viral set point

31 March 2020

1 reference

Fully differentiated HIV-1 specific CD8+ T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection

31 March 2020

1 reference

HIV-1 specific CD8+ T cells with an effector phenotype and control of viral replication

31 March 2020

1 reference

Proliferative capacity of epitope-specific CD8 T-cell responses is inversely related to viral load in chronic human immunodeficiency virus type 1 infection

31 March 2020

1 reference

Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control

31 March 2020

1 reference

Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control

31 March 2020

1 reference

Suppression of HIV replication by lymphoid tissue CD8+ cells correlates with the clinical state of HIV-infected individuals

31 March 2020

1 reference

Viral Inhibition Assay: A CD8 T Cell Neutralization Assay for Use in Clinical Trials of HIV‐1 Vaccine Candidates

31 March 2020

2 references

31 March 2020

12 December 2020

HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells

1 reference

Minor viral and host genetic polymorphisms can dramatically impact the biologic outcome of an epitope-specific CD8 T-cell response

31 March 2020

1 reference

Despite biased TRBV gene usage against a dominant HLA B57-restricted epitope, TCR diversity can provide recognition of circulating epitope variants

31 March 2020

1 reference

PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression

31 March 2020

1 reference

PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection

31 March 2020

1 reference

Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction

31 March 2020

1 reference

CD8+ T-cell responses to different HIV proteins have discordant associations with viral load

31 March 2020

1 reference

Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads

31 March 2020

1 reference

Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control

31 March 2020

1 reference

Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS

31 March 2020

1 reference

Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection

31 March 2020

1 reference

HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors

31 March 2020

1 reference

Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection

31 March 2020

1 reference

HIV-1 Epitope-Specific CD8+ T Cell Responses Strongly Associated with Delayed Disease Progression Cross-Recognize Epitope Variants Efficiently

31 March 2020

1 reference

Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1

31 March 2020

1 reference

Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication

31 March 2020

1 reference

Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection

31 March 2020

1 reference

Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells

31 March 2020

1 reference

Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection

31 March 2020

1 reference

The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection

31 March 2020

1 reference

HIV evolution: CTL escape mutation and reversion after transmission

31 March 2020

1 reference

Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients

31 March 2020

1 reference

Evolution and transmission of stable CTL escape mutations in HIV infection

31 March 2020

1 reference

Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda

31 March 2020

1 reference

Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda

31 March 2020

1 reference

Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection

31 March 2020

1 reference

Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1.

31 March 2020

1 reference

Power to detect the effects of HIV vaccination in repeated low-dose challenge experiments

31 March 2020

1 reference

The use of nonhuman primate models in HIV vaccine development

31 March 2020

1 reference

Highly pathogenic SHIVs and SIVs target different CD4+ T cell subsets in rhesus monkeys, explaining their divergent clinical courses

31 March 2020

1 reference

Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials

31 March 2020

1 reference

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis

31 March 2020

1 reference

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

31 March 2020

1 reference

Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge

31 March 2020

1 reference

Measuring HIV-1-specific T cell immunity: how valid are current assays?

31 March 2020

1 reference

The role of IFN-gamma Elispot assay in HIV vaccine research

31 March 2020

1 reference

Reduced HIV risk-taking and low HIV incidence after enrollment and risk-reduction counseling in a sexually transmitted disease prevention trial in Nairobi, Kenya

31 March 2020

1 reference

Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study

31 March 2020

1 reference

A framework for assessing immunological correlates of protection in vaccine trials.

31 March 2020

1 reference

The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise

31 March 2020

1 reference

New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS.

31 March 2020

1 reference

12 December 2020

Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome

1 reference

12 December 2020

Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T lymphocytes.

1 reference

12 December 2020

Suppression of human immunodeficiency virus type 1 replication by CD8+ cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms

1 reference

12 December 2020

Standardization and validation issues of the ELISPOT assay

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRI2890

1 reference

PubMed ID

21164527

Dimensions Publication ID

24 November 2017

0 references

1 reference

PubMed ID

21164527